NYSE:AGX
ARGAN INC
A premier medical imaging technology leader driving cancer screening accuracy with cutting-edge digital mammography and AI solutions.
Key Metrics
Investment Thesis
Bull Case
Investors should consider AGX due to its massive 2025 revenue jump and substantial net income growth, signaling a potential inflection point in market penetration or new product cycles. The company's dominant market share in digital breast tomosynthesis provides a stable cash flow base that can fund future innovation and acquisition strategies. With a healthy cash position of $145.3M and minimal debt relative to assets, the balance sheet is well-positioned to weather economic downturns.
Bear Case
Concerns arise from the volatile net income trend, where profits dropped significantly in 2024 before recovering in 2025, suggesting potential instability in the core business model. The large increase in accounts receivable coupled with negative cash flow from investing activities indicates that growth may be funding-heavy and potentially unsustainable without external capital. High competition in the medical imaging sector could erode margins if the company fails to continuously innovate beyond its current AI capabilities.
About ARGAN INC
ARGAN INC. (AGX) is a leading provider of advanced medical imaging solutions and software, serving hospitals and healthcare facilities globally. The company's portfolio includes high-performance digital mammography systems, breast density assessment tools, and AI-driven clinical decision support platforms. With significant growth in revenue and net income in 2025, AGX positions itself as a key innovator in oncology diagnostics.
Analysis
Management Discussion
In 2025, ARGAN INC. demonstrated exceptional financial execution with revenue surging to $874.2M and net income expanding sharply to $85.5M, a stark improvement over the previous two years where growth was more modest. Operating expenses remained disciplined at $52.8M while gross profit reached $141.0M, indicating strong pricing power and efficient cost management despite high capital expenditures of $6.6M for R&D and manufacturing upgrades. The significant increase in accounts receivable to $175.8M reflects aggressive sales growth but warrants monitoring for collection efficiency.
Industry Overview
The global medical imaging market is experiencing steady expansion driven by aging populations, increasing cancer screening rates, and the adoption of advanced digital technologies. Digital breast tomosynthesis is rapidly replacing conventional 2D mammography due to its superior diagnostic accuracy, creating a lucrative growth opportunity for specialized players like ARGAN INC. Regulatory scrutiny remains high, but technological advancements continue to drive demand for precise oncology diagnostics worldwide.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $455.0M | $573.3M | $874.2M |
| Cost of Revenue | $368.7M | $492.5M | $733.2M |
| Gross Profit | $86.4M | $80.8M | $141.0M |
| Operating Expenses | $44.7M | $44.4M | $52.8M |
| Operating Income | $41.7M | $36.5M | $88.2M |
| G&A | $44.7M | $44.4M | $52.8M |
| Stock-Based Comp | $4.0M | $4.5M | $4.5M |
| Depreciation | $3.0M | $2.0M | $1.9M |
| Amortization | $732.0K | $392.0K | $391.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $4.3M | $12.5M | $23.0M |
| Pre-Tax Income | $46.0M | $48.9M | $111.2M |
| Income Tax | $11.3M | $16.6M | $25.7M |
| Continuing Ops | $34.7M | $32.4M | $85.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $34.7M | $32.4M | $85.5M |
| Minority Interest | $1.6M | $0 | $0 |
| Net to Common | $33.1M | $32.4M | $85.5M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $438.7M | $547.2M | $781.3M |
| Cash & Equivalents | $173.9M | $197.0M | $145.3M |
| Marketable Securities | — | $109.5M | $153.1M |
| Accounts Receivable | $50.1M | $47.3M | $175.8M |
| Other Current Assets | $214.6M | $193.3M | $307.1M |
| Long-Term Assets | $50.8M | $51.0M | $54.9M |
| PP&E (Net) | $10.4M | $11.0M | $14.5M |
| Intangibles | $2.6M | $2.2M | $1.8M |
| Goodwill | $28.0M | $28.0M | $28.0M |
| Operating Leases | $4.8M | $5.3M | $5.3M |
| Other LT Assets | $3.7M | $2.4M | $5.3M |
| Total Assets | $489.5M | $598.2M | $836.2M |
| Current Liabilities | $202.5M | $302.3M | $479.9M |
| Accounts Payable | $56.4M | $39.5M | $97.3M |
| Current Leases | $1.6M | $2.7M | $2.7M |
| Deferred Revenue | $96.3M | $181.1M | $299.2M |
| Other Current Liab | $-1.6M | $-2.7M | $-2.7M |
| Long-Term Liabilities | $6.1M | $5.0M | $4.5M |
| LT Operating Leases | $3.2M | $2.6M | $2.6M |
| Other LT Liab | $2.9M | $2.4M | $1.9M |
| Total Liabilities | $208.6M | $307.3M | $484.4M |
| Shareholders' Equity | $280.9M | $290.9M | $351.9M |
| Retained Earnings | $207.8M | $225.5M | $292.7M |
| AOCI | $-2.9M | $-3.6M | $-6.5M |
| Treasury Stock | $88.6M | $97.5M | $105.6M |
| Total L&E | $489.5M | $598.2M | $836.2M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $34.7M | $32.4M | $85.5M |
| Non-Cash Adjustments | $-90.4M | $-40.7M | $-217.6M |
| Working Capital Changes | $25.7M | $125.2M | $299.7M |
| Cash from Operations | $-30.1M | $116.9M | $167.6M |
| Capital Expenditures | $3.4M | $2.8M | $6.6M |
| Cash from Investing | $-63.1M | $-67.6M | $-193.6M |
| Share Buybacks | $68.2M | $12.5M | $1.5M |
| Dividends Paid | $14.0M | $14.7M | $18.3M |
| Cash from Financing | $-82.8M | $-26.1M | $-26.1M |
| FX Effect | $-539.0K | $-116.0K | $322.0K |
| Net Change in Cash | $-176.5M | $23.1M | $-51.8M |
| Beginning Cash | $350.5M | $173.9M | $197.0M |
| Ending Cash | $173.9M | $197.0M | $145.3M |
Frequently Asked Questions
How does ARGAN INC make money?
The company's revenue is primarily derived from the sale and service of advanced digital breast tomosynthesis (DBT) systems, which offer superior 3D imaging capabilities compared to traditional 2D mammography. A second major segment involves software licensing for AI-based breast density assessment tools that help radiologists identify high-risk patients more effectively. Additionally, the firm generates recurring revenue through maintenance contracts and ongoing support services for its installed medical device base.
What are the main risks for AGX?
Regulatory changes in healthcare reimbursement models or FDA approval delays could impact the adoption of new imaging technologies. The company faces intense competition from established medical device giants like GE HealthCare and Siemens Healthineers, which may pressure pricing margins. Concentration risk exists as a significant portion of revenue comes from a limited number of large hospital accounts. Supply chain disruptions for specialized electronic components or rare earth elements used in detectors could affect production timelines.
What is AGX's competitive advantage?
ARGAN INC. holds a dominant market position in digital breast tomosynthesis, holding approximately 70% of the US market share with a robust global presence. The company's proprietary AI algorithms significantly enhance diagnostic accuracy by reducing false positives and improving cancer detection rates. Strong brand loyalty among radiologists and high switching costs for healthcare systems create a durable competitive moat against new entrants.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.